Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 26th Preview)
-
Alzheimer’s diagnostics expand with new Roche-Lilly FDA clearance and competitive landscape
The FDA cleared a new blood test for Alzheimer’s from Roche and Eli Lilly, aimed at ruling in and ruling out amyloid pathology using phosphorylated tau 217 (pTau217) levels. Roche’s Elecsys pTau217 assay, already cleared in Europe, is designed for people age 55 and older with signs of cognitive decline. Labcorp and Quest Diagnostics said they plan to offer the test, positioning the assay for broad access beyond specialty centers. The clearance adds to momentum from earlier FDA decisions on blood-based tau/amyloid tests, including Fujirebio’s Lumipulse in 2025 and C2N Diagnostics’ PrecivityAD2. Analysts framed the new launch as a signal of rising competition in Alzheimer’s blood diagnostics, with assay standardization and instrument compatibility emerging as differentiators. Roche said the test uses validated clinical cutoffs across settings and is built for Cobas lab systems.
-
FDA approvals broaden Jazz’s Ziihera into frontline gastric cancer and expand market access
Jazz Pharmaceuticals won an FDA label expansion for Ziihera, moving the bispecific antibody into a frontline regimen for certain gastric cancer patients. The approval makes Ziihera a newly marketed option for patients starting first-line therapy, after its earlier use in later-line settings. RBC and Stifel analysts highlighted commercial implications, including the competitive pressure from HER2 antibody biosimilars and the possibility of broader uptake in additional gastrointestinal indications. The company’s development strategy also centers on consistent clinical cutoffs and label language designed for real-world deployment. Separately, Jazz’s Ziihera reached the market earlier through an accelerated pathway for biliary tract cancer, setting up the current expansion as a step toward a larger total addressable population. The company continues to pair Ziihera with chemotherapy and, in some regimens, immunotherapy.
-
J&J’s Imaavy becomes first approved therapy for warm autoimmune hemolytic anemia in label expansion moves
Johnson & Johnson’s Imaavy received a US label expansion for warm autoimmune hemolytic anemia (wAIHA), positioning it as the first FDA-approved therapy specifically for the rare autoimmune condition. The antibody drug was originally cleared the prior year for generalized myasthenia gravis. The expansion moves Imaavy closer to multi-indication scale and signals J&J’s broader strategy of building franchise value through antibody reuse across immune-mediated diseases. For clinicians, the decision also provides a new treatment option in wAIHA, where there is ongoing need for targeted, durable disease control. Market participants will watch uptake and real-world prescribing, especially given the overlap of wAIHA management with existing immunosuppressive approaches and the need to define sequencing in clinical practice.
-
Roche, Eli Lilly and broader blood-based biomarker momentum intensifies Alzheimer’s diagnostics competition
Alzheimer’s blood testing momentum accelerated again as FDA cleared additional biomarker assays and diagnostic players moved to integrate them into routine lab workflows. Analysts pointed to a shift toward earlier placement in the diagnostic pathway when PET and CSF testing are less accessible. Roche and Eli Lilly’s clearance adds to a growing catalog of tau/amyloid blood tests, with companies increasingly emphasizing consistent clinical cutoffs across patient populations and instrument platforms. Lab operators’ commitments to nationwide rollout reflect a push to scale adoption. In parallel, market focus is shifting toward assay comparability and test positioning relative to confirmatory imaging, with the latest approvals shaping how clinicians order next-step evaluations.
-
Multiple myeloma: teclistamab T-cell engager delivers major progression and survival benefit in MajesTEC-9
Janssen Research & Development reported major results from the MajesTEC-9 Phase I/IIa trial of teclistamab in refractory multiple myeloma. In the study’s reported interim outcomes, teclistamab met its primary endpoint, improving progression-free and overall survival compared with control therapies. The company highlighted response depth, including high complete response rates and a substantial share of patients reaching minimal residual disease (MRD) negativity. MRD negativity is widely used as a marker of deep clearance in multiple myeloma and has been correlated with long-term outcomes. With nearly 600 patients included in the cohort, the results reinforce the rapid expansion of T-cell engaging strategies in myeloma treatment and fuel expectations for next steps in late-stage confirmatory development and label expansion.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.